Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Review proposal consultation

Stakeholder matrix (PDF 36 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: equality impact assessment - guidance development

Macular oedema (retinal vein occlusion) - ranibizumab: final appraisal determination information

Macular oedema (retinal vein occlusion) - ranibizumab: final appraisal determination document

Macular oedema (retinal vein occlusion) - ranibizumab: final appraisal determination document (PDF 279 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Macular oedema (retinal vein occlusion) - ranibizumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 518 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: consultee and commentator comments on the ACD

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis (PDF 608 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: RNIB

Macular oedema (retinal vein occlusion) - ranibizumab: RNIB (PDF 18 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing (PDF 26 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists (PDF 108 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wiltshire

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wiltshire (PDF 32 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wirral

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wirral (PDF 21 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Allergan

Macular oedema (retinal vein occlusion) - ranibizumab: Allergan (PDF 86 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: BMJ group

Macular oedema (retinal vein occlusion) - ranibizumab: BMJ group (PDF 73 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: expert comments on the  ACD

Macular oedema (retinal vein occlusion) - ranibizumab: Gibson

Macular oedema (retinal vein occlusion) - ranibizumab: Gibson (PDF 64 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Sivaprasad

Macular oedema (retinal vein occlusion) - ranibizumab: Sivaprasad (PDF 20 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: comments on the ACD received from the public through the NICE website

Macular oedema (retinal vein occlusion) - ranibizumab: comments on the ACD received from the public through the NICE website (PDF 63 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: ERG Critique of Novartis ACD Comments

Macular oedema (retinal vein occlusion) - ranibizumab: ERG Critique of Novartis ACD Comments (PDF 316 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Specification

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Specification (PDF 38 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Report

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Report (PDF 1.43 MB)

Macular oedema (retinal vein occlusion) - ranibizumab: comments on the DSU Report

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis DSU comments (PDF 166 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Macular Disease Society DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Macular Disease Society DSU comments (PDF 19 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: RNIB DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: RNIB DSU comments (PDF 68 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing DSU comments (PDF 23 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists DSU comments (PDF 156 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wiltshire DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wiltshire DSU comments (PDF 31 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Commissioning Support Appraisals Service DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Commissioning Support Appraisals Service DSU comments (PDF 216 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Allergan DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Allergan DSU comments (PDF 76 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Roche DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Roche DSU comments (PDF 59 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Manufacturer Revised Patient Access Scheme submission

Macular oedema (retinal vein occlusion) - ranibizumab: Manufacturer Revised Patient Access Scheme submission (PDF 327 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: ERG Critique of Patient Access Scheme submission

Macular oedema (retinal vein occlusion) - ranibizumab: appraisal consultation

Macular oedema (retinal vein occlusion) - ranibizumab: appraisal consultation document information

Macular oedema (retinal vein occlusion) - ranibizumab: evaluation report

Macular oedema (retinal vein occlusion) - ranibizumab: pre-meeting briefing

Macular oedema (retinal vein occlusion) - ranibizumab: pre-meeting briefing (PDF 410 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Evidence Review Group report

Macular oedema (retinal vein occlusion) - ranibizumab: ERG report

Macular oedema (retinal vein occlusion) - ranibizumab: ERG report (PDF 2.79 MB)

Macular oedema (retinal vein occlusion) - ranibizumab: ERG report erratum

Macular oedema (retinal vein occlusion) - ranibizumab: ERG report erratum (PDF 375 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: additional ERG report

Macular oedema (retinal vein occlusion) - ranibizumab: additional ERG report (PDF 54 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Evidence Review Group - factual accuracy check

Macular oedema (retinal vein occlusion) - ranibizumab: Evidence Review Group - factual accuracy check (PDF 157 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: manufacturer submission

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis submission

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis submission (PDF 4.87 MB)

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis PAS submission

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis PAS submission (PDF 375 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: clarification

Macular oedema (retinal vein occlusion) - ranibizumab: NICE clarification letter

Macular oedema (retinal vein occlusion) - ranibizumab: NICE clarification letter (PDF 343 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: manufacturer response to NICE clarification questions

Macular oedema (retinal vein occlusion) - ranibizumab: manufacturer response to the NICE clarification letter

Macular oedema (retinal vein occlusion) - ranibizumab: manufacturer response to the NICE clarification letter (PDF 1.23 MB)

Macular oedema (retinal vein occlusion) - ranibizumab: report

Macular oedema (retinal vein occlusion) - ranibizumab: report (PDF 975 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: patient group, professional group and NHS organisation submission statements

Macular oedema (retinal vein occlusion) - ranibizumab: Royal National Institute of Blind People (RNIB)

Macular oedema (retinal vein occlusion) - ranibizumab: organisation statement

Macular oedema (retinal vein occlusion) - ranibizumab: organisation statement (PDF 101 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study A

Macular oedema (retinal vein occlusion) - ranibizumab: case study A (PDF 34 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study B

Macular oedema (retinal vein occlusion) - ranibizumab: case study B (PDF 6.4 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study C

Macular oedema (retinal vein occlusion) - ranibizumab: case study C (PDF 34 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study D

Macular oedema (retinal vein occlusion) - ranibizumab: case study D (PDF 9 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study E

Macular oedema (retinal vein occlusion) - ranibizumab: case study E (PDF 10 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing (PDF 140 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists (RCOPHTH)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists (RCOPHTH) (PDF 125 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wirral

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wirral (PDF 66 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: expert written personal statements

Macular oedema (retinal vein occlusion) - ranibizumab: Gibson

Macular oedema (retinal vein occlusion) - ranibizumab: Gibson (PDF 30 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Keeley

Macular oedema (retinal vein occlusion) - ranibizumab: Keeley (PDF 24 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Pearce

Macular oedema (retinal vein occlusion) - ranibizumab: Pearce (PDF 169 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Sivaprasad

Macular oedema (retinal vein occlusion) - ranibizumab: Sivaprasad (PDF 119 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Winyard

Macular oedema (retinal vein occlusion) - ranibizumab: final scope

Macular oedema (retinal vein occlusion) - ranibizumab: final matrix

Macular oedema (retinal vein occlusion) - ranibizumab: equality impact assement - scoping

Macular oedema (retinal vein occlusion) - ranibizumab: draft scope for rescope consultation

Macular oedema (retinal vein occlusion) - ranibizumab: provisional matrix for rescope consultation

Appendix B: draft scope for consultation (pre-referral) 

Appendix C: provisional matrix (pre-referral)